Adma Biologics (ADMA) Cash from Operations Growth (3y) (2016 - 2025)
Adma Biologics (ADMA) Cash from Operations Growth (3y) (2016 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 34.32% |
| 10 | Adma Biologics | 2.05 Bn | 1.96 Bn | 88.82 Mn | 89.73% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 89.73% |
| Sep 30, 2025 | 44.23% |
| Jun 30, 2025 | 53.93% |
| Mar 31, 2025 | 8.89% |
| Dec 31, 2024 | 51.84% |
| Sep 30, 2024 | 56.95% |
| Jun 30, 2024 | 50.59% |
| Mar 31, 2024 | 59.44% |
| Dec 31, 2023 | 36.55% |
| Sep 30, 2023 | 35.77% |
| Jun 30, 2023 | 34.22% |
| Mar 31, 2023 | 15.78% |
| Dec 31, 2022 | 27.86% |
| Sep 30, 2022 | 17.47% |
| Jun 30, 2022 | 11.68% |
| Mar 31, 2022 | -22.11% |
| Dec 31, 2021 | -21.21% |
| Sep 30, 2021 | -2.26% |
| Jun 30, 2021 | -29.35% |
| Mar 31, 2021 | -26.45% |